z.okonkwo

TL2 · Palermo

Contributes reviews on supplier material. Based in Palermo.

Joined 12 September 2025 · last posted 4d

84 posts, newest first. Showing up to 150.

A pooled estimate that changed when one trial was added Replied, post #28 · Evidence › Meta-analyses · 24 Jul 2026 · 30 likes Inclusion and exclusion criteria: a meta-analysis is only as good as its inclusion criteria. If the criteria are too broad, apples and oranges get pooled. If they are…
Revisiting: The best-written scientific paper you have read Replied, post #108 · Lounge › Off topic · 22 Jul 2026 · 5 likes Source for the best-written scientific paper figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is…
Prior authorisation: what the criteria usually require — a second dataset Replied, post #50 · Access › Insurance & coverage · 21 Jul 2026 · 0 likes Counterpoint on Prior authorisation, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #52 · Analytics › HPLC & UHPLC · 20 Jul 2026 · 17 likes Small correction to my own earlier position on Detection wavelength. I had the units the wrong way round, which changes the conclusion by an order of magnitude and…
Tracking semaglutide's approved indications across jurisdictions, dated Replied, post #18 · Compounds › Semaglutide · 18 Jul 2026 · 4 likes Post #16 and I disagree about the size of the effect, not about the direction. The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a…
Second pass at: What a 2 ppm match establishes, and what it does not Replied, post #45 · Analytics › Mass spectrometry · 17 Jul 2026 · 17 likes Post #41 put the caveat in the right place and I want to underline it. Purity and identity are different questions: LC-MS establishes that the species at a retention…
Reading a home test result without over-claiming Replied, post #120 · Analytics › Home & field testing · 15 Jul 2026 · 21 likes A home refractometer is not measuring what people hope it is measuring in these preparations, and the readings are dominated by everything other than the peptide.…
A structured critique template this community uses Started this topic · Evidence › Study critique · 15 Jul 2026 · 7 likes A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Structured critique template — I have the…
Constipation management, with a dietitian's contribution Replied, post #89 · Practice › Side effects · 7 Jul 2026 · 0 likes The arithmetic in post #87 is right; the assumption feeding it is the part to check. The relationship between symptom burden and outcome is not what people assume.…
What to bring: records that a clinician can actually use — a second dataset Replied, post #10 · Clinical › Prescriber conversations · 6 Jul 2026 · 2 likes Building on post #9 rather than restating it. Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label…
What I would want from a home test that does not exist yet Replied, post #23 · Analytics › Home & field testing · 29 Jun 2026 · 24 likes Post #19 and I disagree about the size of the effect, not about the direction. Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An…
Journal club: LEADER as the historical anchor Replied, post #90 · Evidence › Journal club · 16 Jun 2026 · 0 likes Confirming post #88 from a second method, which matters more than confirming it from a second person. A note on how LEADER gets discussed rather than on LEADER itself:…
Coming back to: A structured critique template this community uses Replied, post #29 · Evidence › Study critique · 9 Jun 2026 · 0 likes I think the structured critique template question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Hair shedding at month three: mechanism and time course — the long version Replied, post #8 · Practice › Side effects · 8 May 2026 · 0 likes Hair shedding: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know…
Second pass at: When your prescriber and the evidence disagree Replied, post #16 · Clinical › Prescriber conversations · 30 Apr 2026 · 0 likes Post #14 put the caveat in the right place and I want to underline it. Bringing a record of symptoms with dates and severities makes an assessment materially easier and…
Second pass at: What "verified" means on our vendor pages, stated narrowly Replied, post #100 · Sourcing › Vendor reports · 27 Apr 2026 · 26 likes Dosing and purity: a vial that is 99% pure might contain 80% of its label claim if the other mass is water, counter-ion, and excipient. Purity and content are…
Citation sweep results: how many references did not say what was claimed Replied, post #79 · Meta › Wiki maintenance · 17 Apr 2026 · 30 likes Right — I had this wrong and I am glad to have read it before it mattered.
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #104 · Pharmacology › Pharmacokinetics · 13 Apr 2026 · 0 likes Worth stating the null on Washout before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
A site rotation scheme that is easy enough to actually follow Replied, post #39 · Practice › Administration · 12 Apr 2026 · 4 likes If you have to inject at a different time of day than usual, that is a much smaller perturbation than it feels for a weekly compound with a week-long half-life.
[2026 update] Composite endpoints and the component doing the work Replied, post #61 · Evidence › Trials · 8 Apr 2026 · 21 likes That is a fair summary of where the discussion has got to.
Managing an unplanned gap in supply Replied, post #49 · Access › Shortages · 4 Mar 2026 · 4 likes For anyone finding this later: the short answer on managing an unplanned gap is that it depends on one thing, and the rest of the thread is people identifying which…
Type 2 diabetes and the largest part of the evidence base Replied, post #17 · Clinical › Comorbidities · 1 Mar 2026 · 6 likes Useful. I have added it to my own notes with the date on it.
Five questions in one post gets you one answer — how to split them Replied, post #10 · Start Here › How to Ask · 10 Feb 2026 · 12 likes Two sentences on five questions and then I will stop, because the rest is speculation and the thread is better without mine. What is documented is narrow. What is…
Warfarin and altered intake: the monitoring argument — the long version Replied, post #104 · Practice › Interactions · 4 Feb 2026 · 2 likes A pharmacist can answer most questions in this subcategory in a few minutes with access to a proper interaction database, and that access is the thing a forum does not…
Follow-up: The retatrutide phase 2 obesity paper, read closely Replied, post #2 · Compounds › Retatrutide · 3 Feb 2026 · 15 likes Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that…
What "verified" means on our vendor pages, stated narrowly Replied, post #24 · Sourcing › Vendor reports · 31 Dec 2025 · 7 likes Coming back to post #20, because the follow-up matters more than the original answer. Do not adjust a reported figure. Post what the laboratory said and put your…
Revisiting: Language barriers in accessing a prescription abroad Replied, post #26 · Access › International · 26 Dec 2025 · 25 likes Where I part company with post #24, and it is a narrow parting. A regional experience posted here should say which year it describes. The archive keeps these…
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset Replied, post #15 · Sourcing › Independent verification · 24 Dec 2025 · 7 likes This follows post #14 rather than contradicting it. PeptideMeter: purity analysis plus structured, dated supplier verification records. Produces both individual…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #56 · Clinical › Special populations · 20 Dec 2025 · 1 like Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is…
Cost per delivered dose, which is the number that matters Replied, post #29 · Access › Pricing · 11 Dec 2025 · 0 likes Clear enough that I do not think I have a follow-up, which is unusual.
Tracking a preprint to publication: a worked example Replied, post #75 · Evidence › Preprints · 7 Dec 2025 · 0 likes Post #73 answers the question as asked. The question underneath it is different. Do not build anything on a preprint that you would mind rebuilding: if the preprint…
Lean mass preservation: what the evidence supports — does this still hold? Started this topic · Outcomes › Body composition · 6 Dec 2025 · 43 likes Asking directly, because I could not find a straight answer: Lean mass preservation: what the evidence supports — does this still hold? What changes if the standard…
A preprint whose numbers changed substantially at publication — what changed since Replied, post #8 · Evidence › Preprints · 4 Dec 2025 · 0 likes Understood. Thank you for being specific about the limits of it.
Whether protein timing matters at a large deficit Replied, post #5 · Nutrition & Training › Protein & intake · 27 Nov 2025 · 5 likes The practical problem is that appetite suppression makes hitting a target genuinely hard, and "eat more protein" ignores the actual constraint. The interesting part of…
Publishing an inconvenient result: a case study — the long version Replied, post #49 · Sourcing › Independent verification · 25 Nov 2025 · 17 likes Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not…
Coming back to: Injection-site reactions: describing them precisely enough to be useful Replied, post #13 · Practice › Side effects · 23 Nov 2025 · 7 likes Two things can be true about Injection-site reactions at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here…
Lurking for two months before posting: was that the right call? Replied, post #58 · Start Here › Welcome · 20 Nov 2025 · 23 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Alcohol: what is documented and what is folklore — the long version Replied, post #4 · Practice › Interactions · 16 Nov 2025 · 15 likes Post #3 answers the question as asked. The question underneath it is different. On Alcohol, the part that usually goes wrong is that the question is asked as though it…
Reading a supplier's product description as a marketing document Replied, post #96 · Compounds › Other compounds · 10 Nov 2025 · 0 likes Storage guidance for the less common material is usually copied from the incretin guidance and may not apply. Where the supplier has its own stability statement, that…
What a purity-only report leaves out Replied, post #69 · Sourcing › Independent verification · 1 Nov 2025 · 3 likes Careful with the language on purity-only. "Not detected" and "not present" are different findings and the first is a statement about the method.
Angle of injection and whether 90 degrees is always right Replied, post #42 · Practice › Administration · 28 Oct 2025 · 15 likes Everything in post #40 holds. The case it does not cover is the one I have. Alcohol swabbing and letting the site dry is the whole of the preparation for a subcutaneous…
Follow-up: What a seizure notice actually says Replied, post #14 · Sourcing › Logistics · 25 Oct 2025 · 0 likes Narrowing post #13, because the general version has more than one answer. Adding a small correction to the seizure notice summary above rather than a disagreement with…
Sleep tracking data and its considerable limitations Replied, post #61 · Wellbeing › Sleep · 22 Oct 2025 · 0 likes Apnoea monitoring: if you have diagnosed or suspected sleep apnoea, periodic monitoring (annually) during weight loss is prudent because severity changes.
Journal club: indirect comparison between two programmes, defended and attacked — one… Replied, post #46 · Evidence › Journal club · 17 Oct 2025 · 0 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
Revisiting: German, French and Dutch differences, compared Replied, post #85 · Regional › European Union · 11 Oct 2025 · 17 likes Adding a null result on German. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
What a regulator's shortage notice actually authorises — what changed since Replied, post #10 · Sourcing › Regulatory · 2 Oct 2025 · 30 likes Adding thanks rather than a view. I do not have a view worth the space.
[2026 update] Does dual agonism explain the effect size, or is it dose? Replied, post #30 · Compounds › Tirzepatide · 27 Sep 2025 · 28 likes No notes. Posting so the count is not one.
A checklist for reading a certificate in under two minutes — does this still hold? Replied, post #46 · Analytics › COA interpretation · 19 Sep 2025 · 4 likes No notes. Posting so the count is not one.
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #71 · Analytics › HPLC & UHPLC · 15 Sep 2025 · 0 likes The honest answer on Resolution and tailing factor is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much…
A ten-fold dose error caught before injection Replied, post #68 · Devices › Syringes & needles · 20 Jul 2025 · 1 like Appreciated. The plain phrasing does more work here than a longer post would.
Asking about a compound your prescriber has not heard of Replied, post #97 · Clinical › Prescriber conversations · 17 Jul 2025 · 9 likes Picking up post #95: that is the part I would want checked first. A question phrased as "what would you want to see before considering X" is answerable and is not a…
About the Trials category Replied, post #4 · Evidence › Trials · 15 Jul 2025 · 0 likes Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for…
Revisiting: Early satiety becoming a problem rather than a benefit Replied, post #2 · Practice › Side effects · 14 Jul 2025 · 30 likes Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound…
Why quantitation is the hard part, not detection Replied, post #14 · Analytics › Home & field testing · 22 Jun 2025 · 18 likes Quantitation: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
[2026 update] An appeal that failed, and what I would do differently Replied, post #90 · Access › Insurance & coverage · 13 Jun 2025 · 1 like Appeal has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Follow-up: Tracking intake honestly when appetite is absent Replied, post #71 · Nutrition & Training › Protein & intake · 12 Jun 2025 · 15 likes The mechanism is not mysterious. Substantial energy restriction with inadequate protein and no resistance stimulus loses lean tissue as well as fat.
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #8 · Compounds › Cagrilintide & amylin analogues · 3 Jun 2025 · 0 likes Appreciated. The plain phrasing does more work here than a longer post would.
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #16 · Practice › Reconstitution · 29 May 2025 · 0 likes Worked example, since the arithmetic is the whole question. Five milligrams into one millilitre is 5 mg/mL. A 0.25 mg dose is 0.05 mL, which is five units on a U-100…
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #15 · Evidence › Journal club · 25 May 2025 · 0 likes Narrowing post #12, because the general version has more than one answer. Bringing the previous paper on the same question makes the session much better and doubles the…
Second pass at: Designing a personal experiment that could change your mind Replied, post #29 · Research Methods › N-of-1 designs · 20 May 2025 · 21 likes An n of one tells you about one person, which is the person you are most interested in. That is the whole value and it is not nothing. One of those cases where knowing…
Follow-up: What other technical communities get right that we do not Replied, post #100 · Lounge › Off topic · 17 May 2025 · 24 likes Not a technical point, just an observation: the register here holds because people correct themselves in public and nobody scores points off it. That is rarer than the…
Reading a trial's population section before its results — does this still hold? Replied, post #94 · Evidence › Trials · 12 May 2025 · 2 likes The first question about any trial is what it set out to estimate, not what it found. Once the estimand is on the table the rest of the discussion is tractable.
DXA precision and the least significant change for lean mass — the long version Replied, post #30 · Outcomes › Body composition · 11 May 2025 · 24 likes Where I part company with post #27, and it is a narrow parting. Practical experience of DXA precision, offered as one case with the conditions stated, not as a general…
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #46 · Compounds › Retatrutide · 4 May 2025 · 0 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #64 · Compounds › Tirzepatide · 18 Apr 2025 · 0 likes On tirzepatide in type 2 diabetes the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Publishing an inconvenient result: a case study Replied, post #9 · Sourcing › Independent verification · 17 Apr 2025 · 19 likes Asking the supplier before publishing a discrepancy is the convention here. Most discrepancies are explained by handling or method and asking costs a day. Worth one…
Certificates issued by the seller versus by a laboratory Replied, post #11 · Analytics › COA interpretation · 19 Mar 2025 · 0 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Charge states for a 4 kDa peptide, worked through Replied, post #56 · Analytics › Mass spectrometry · 9 Mar 2025 · 0 likes Building on post #55 rather than restating it. Positional isomers and epimers are mass-identical. Any argument that a mass result rules them out is wrong, and it is the…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #74 · Compounds › Semaglutide · 23 Feb 2025 · 2 likes Post #73 answers the question as asked. The question underneath it is different. Research-use-only semaglutide is not a licensed medicine, is not manufactured to…
Reading a supplementary appendix and finding the interesting part Replied, post #93 · Evidence › Trials · 14 Feb 2025 · 0 likes Taking post #92 at face value and following it one step further. Composite endpoints should be read component by component. A composite driven entirely by its softest…
Escalating every six weeks instead of four: what I observed over eight months Replied, post #11 · Practice › Dosing & titration · 8 Jan 2025 · 32 likes I would put moderate confidence on the mainstream reading of escalating every six weeks instead and no more. That is not scepticism for its own sake; it is where the…
Telehealth prescribing models in the US Replied, post #40 · Regional › North America · 1 Jan 2025 · 21 likes On post #38 — agreed on the reasoning, with one qualification. Before the thread moves on from telehealth prescribing models — what is the sample size behind the claim?…
Follow-up: Dead volume across syringe and needle combinations Replied, post #91 · Devices › Syringes & needles · 30 Dec 2024 · 16 likes Dead volume: residual liquid in the hub and needle after withdrawal. Typical residual is 0.01 to 0.02 mL for an insulin syringe with a fixed needle. Accounting for it…
A newcomer's list of things that confused me, and the fixes Replied, post #3 · Start Here › Welcome · 17 Dec 2024 · 32 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #85 · Compounds › Tirzepatide · 13 Dec 2024 · 11 likes Coming back to post #83, because the follow-up matters more than the original answer. Categorical response thresholds — the proportion reaching ten, fifteen or twenty…
Follow-up: Recovery when intake is low: what to cut first Replied, post #37 · Nutrition & Training › Resistance training · 22 Nov 2024 · 18 likes This is the sort of exchange that makes the archive worth searching.
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #38 · Compounds › Semaglutide · 5 Nov 2024 · 33 likes On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species.…
US compounding rules and how they changed Replied, post #20 · Regional › North America · 11 Oct 2024 · 2 likes Clear enough that I do not think I have a follow-up, which is unusual.
Progressive overload when the scale is falling — one year on Replied, post #147 · Nutrition & Training › Resistance training · 11 Oct 2024 · 0 likes Post #145 answers the question as asked. The question underneath it is different. On Progressive overload the community has more anecdote than the confidence in this…
A rising related-substance total over six months: degradation or method drift? Replied, post #29 · Analytics › Impurities & related substances · 3 Sep 2024 · 0 likes Off-target structures: if the sequence synthesis goes wrong, a completely different amino acid can be incorporated. The resulting off-target peptide is a structural…
Criticising the method without criticising the authors Replied, post #2 · Evidence › Study critique · 23 Aug 2024 · 6 likes Statistical significance and clinical importance are different and both are needed. A significant difference below the minimal important difference is a real finding of…
Circumference measurements as a poor man's composition estimate Replied, post #41 · Outcomes › Body composition · 4 Aug 2024 · 0 likes That is a fair summary of where the discussion has got to.
Cold packs, phase-change material, and what survives ten days Replied, post #120 · Sourcing › Logistics · 19 Jul 2024 · 1 like Confirming post #119 from a second method, which matters more than confirming it from a second person. Delivery to an address where somebody is present is worth more…
Second pass at: Journal club: LEADER as the historical anchor Replied, post #33 · Evidence › Journal club · 16 Jul 2024 · 9 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later.